Skip Navigation


European Journal of Echocardiography Advance Access originally published online on September 4, 2008
European Journal of Echocardiography 2008 9(6):719-720; doi:10.1093/ejechocard/jen220
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
9/6/719    most recent
jen220v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Becher, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becher, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Contrast agents for echocardiographic studies within 24 h after myocardial infarction

Harald Becher

Cardiac Investigation Annexe, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford OX3 9DU, UK

Corresponding author. Tel. +44 1865 220 325; fax: +44 1865 740 409. E-mail address: harald.becher@orh.nhs.uk

The first 10% of the full text of this article appears below.


   Back to normal in the US
 
In April 2008, the US Food and Drug Administration (FDA) performed a safety review of the US-approved perflutren microsphere contrast agents (Definity and Optison) and revised a previous black box warning. The new contraindications are much less restrictive than the previous contraindications and satisfy the needs of clinical echocardiography. These changes have come after an intensive debate with the American Society of Echocardiography but also with significant European support. The correction of the contraindication for contrast agents is a good example, how inadequate decisions by the health administration can be reversed by competent and decisive actions of scientific and professional bodies like the ASE and EAE.

Before April 2008, the use of contrast agents was contraindicated in patients with unstable cardiopulmonary status, including patients with unstable angina, acute . . . [Full Text of this Article]


   Back to normal ... not in Europe!
 

   Need for performing a contrast study within 24 h after myocardial infarction
 

   What needs to be done?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
S A Mollema, G Nucifora, and J J Bax
Prognostic value of echocardiography after acute myocardial infarction
Heart, November 1, 2009; 95(21): 1732 - 1745.
[Abstract] [Full Text] [PDF]